At the news
? MIXEDIMPACT 6/10 8-K filed Mar 5, 2026 at 07:16 ET
Tango Therapeutics reported financial results for Q4 and full year 2025, showing a decline in revenue due to the conclusion of its Gilead collaboration, while R&D expenses decreased year-over-year. The company highlighted clinical progress with vopimetostat, including combination trials and a new supply agreement with Erasca, and announced leadership changes. Cash position of $343.1 million provides runway into 2028.
- Revenue dropped to $0 in Q4 2025 from $5.4M in Q4 2024, and full-year revenue decreased to $62.4M from $42.1M in 2024 due to completion of Gilead collaboration
- Net loss narrowed to $38.7M in Q4 2025 from $30.8M in Q4 2024, and full-year net loss decreased to $101.6M from $130.3M in 2024
- Cash, cash equivalents, and marketable securities totaled $343.1 million as of December 31, 2025, providing runway into 2028
- Company initiated a pivotal study for vopimetostat in 2L pancreatic cancer and entered a clinical supply agreement with Erasca for combination therapy
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access